Federal Contractor Profile
Spero Therapeutics, INC.
$60M obligated·3 awards·1 agencies·3 NAICS
Federal Contracts
Showing award actions 1–16 of 16 funded award actions, most recent first.
- Contracts with positive obligations
- 3
- Funded award actions shown
- 16
- Obligations shown
- $60M
- Awarding agencies
- 1
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of July 20, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Jun 17, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $6.4M |
| Aug 23, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $3.4M |
| Jul 3, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $12M |
| Dec 20, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $642K |
| Aug 23, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $85K |
| Aug 8, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $780K |
| Dec 14, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $149K |
| Oct 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $4.0M |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $12M |
| Jan 14, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $13M |
| May 12, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021C00022 | 541715 | TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. | $2.1M |
| Sep 12, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500014C | 541712 | IGF::OT::IGF - "DEVELOPMENT OF A SECOND GENERATION POLYMYXIN FOR THERAPY OF MDR GRAM-NEGATIVE INFECTIONS" | $211K |
| May 19, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $2.5M |
| Aug 3, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500014C | 541712 | IGF::OT::IGF - "DEVELOPMENT OF A SECOND GENERATION POLYMYXIN FOR THERAPY OF MDR GRAM-NEGATIVE INFECTIONS" | $296K |
| Jul 12, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00015 | 541714 | IGF::OT::IGF | $16M |
| Apr 4, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500014C | 541712 | IGF::OT::IGF - "DEVELOPMENT OF A SECOND GENERATION POLYMYXIN FOR THERAPY OF MDR GRAM-NEGATIVE INFECTIONS" | $275K |
Get Alerted Before Spero Therapeutics, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free